BMO Capital on Gilead Sciences (GILD): 'If positive, PURPOSE-2 could allow for an approval of lenacapavir as early as late 2025'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $80.00 price target on Gilead Sciences (NASDAQ: GILD)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
